Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

The outcome of patients with higher‐risk myelodysplastic syndromes (MDS) after hypomethylating agent (HMA) failure is poor. This study evaluated the safety and activity of a combination of low‐dose clofarabine and cytarabine for these patients.

[1]  R. Collins,et al.  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[2]  P. Greenberg,et al.  Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy , 2015, Hematological oncology.

[3]  E. Shpall,et al.  Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  H. Kantarjian,et al.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.

[5]  M. Cazzola,et al.  Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[7]  M. Konopleva,et al.  Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. , 2012, Clinical lymphoma, myeloma & leukemia.

[8]  H. Kantarjian,et al.  Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. , 2012, The Journal of molecular diagnostics : JMD.

[9]  Z. Estrov,et al.  A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher‐risk myelodysplastic syndrome , 2012, Cancer.

[10]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Alan Agresti,et al.  Categorical Data Analysis , 2003 .

[12]  Rajyalakshmi Luthra,et al.  Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. , 2011, American journal of clinical pathology.

[13]  J. Issa,et al.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.

[14]  Z. Estrov,et al.  Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[16]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[17]  Z. Estrov,et al.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. , 2008, Blood.

[18]  H. Kantarjian,et al.  Clofarabine: Past, present, and future , 2007, Leukemia & lymphoma.

[19]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[20]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[21]  E. Estey,et al.  Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. , 2005, Blood.

[22]  H. Kantarjian,et al.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.

[23]  F. Khuri,et al.  Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[25]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .